These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29913885)

  • 1. The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study.
    Hougaard A; Hauge AW; Guo S; Tfelt-Hansen P
    Scand J Pain; 2013 Jan; 4(1):48-52. PubMed ID: 29913885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura?
    Dowson A
    Eur Neurol; 1996; 36 Suppl 2():28-31. PubMed ID: 8791030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs targeting nitric oxide synthase for migraine treatment.
    Barbanti P; Egeo G; Aurilia C; Fofi L; Della-Morte D
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1141-8. PubMed ID: 24818644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models.
    Bhatt DK; Gupta S; Jansen-Olesen I; Andrews JS; Olesen J
    Cephalalgia; 2013 Jan; 33(2):87-100. PubMed ID: 23155193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.
    Hauge AW; Asghar MS; Schytz HW; Christensen K; Olesen J
    Lancet Neurol; 2009 Aug; 8(8):718-23. PubMed ID: 19570717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).
    Winner P; Farkas V; Štillová H; Woodruff B; Liss C; Lillieborg S; Raines S;
    Headache; 2016 Jul; 56(7):1107-19. PubMed ID: 27329280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
    Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ;
    Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura.
    Butt JH; Rostrup E; Hansen AS; Lambertsen KL; Kruuse C
    Brain; 2018 Oct; 141(10):2943-2951. PubMed ID: 30137217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study.
    Noruzzadeh R; Modabbernia A; Aghamollaii V; Ghaffarpour M; Harirchian MH; Salahi S; Nikbakht N; Noruzi N; Tafakhori A
    Headache; 2016 Jan; 56(1):95-103. PubMed ID: 26638119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial.
    Asadollahi S; Heidari K; Vafaee R; Forouzanfar MM; Amini A; Shahrami A
    Headache; 2014 Jan; 54(1):94-108. PubMed ID: 24182419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
    Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
    Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
    Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
    Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
    Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
    Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura.
    Hougaard A; Younis S; Iljazi A; Sugimoto K; Ayata C; Ashina M
    Headache; 2020 Apr; 60(4):724-734. PubMed ID: 31994720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.